Almirall and Microsoft partner on AI-powered drug discovery in dermatology

Almirall S.A., a global pharmaceutical company focused on medical dermatology, announced today a strategic partnership with Microsoft to drive innovation and digital transformation, advance the research of medical solutions for dermatological diseases, and accelerate the digital transformation of the company.

Novel Anti-Inflammatory Flops for HFpEF, HFmrEF

CHICAGO — The novel myeloperoxidase (MPO) inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection

November 19, 2024

Comprehensive analysis of immune checkpoint inhibitors reveals endocrine toxicity patterns

Announcing a new publication for Acta Materia Medica journal. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose a challenge of immune-related adverse events

February 21, 2024

AMA President-Elect Confronts a New Challenge: A Brain Tumor

When he started to notice a couple of things about himself that were “off,” Bobby Mukkamala, MD, president-elect of the American Medical Association (AMA), chalked

November 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.